Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company’s research programs develop diversified pipeline of drug candidates, including GFT505, which completes a Phase 2b study in NASH. The Company’s facilities are located in France and the United States. The Company’s wholly owned subsidiaries include Genfit Corporation, located in Cambridge, the United States and Genfit Pharmaceuticals SAS.